Entera Bio Ltd., a clinical-stage company developing oral peptide therapies, announced that CEO Miranda Toledano will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. The event will be held in Boston and streamed online, providing insights into Entera's innovative oral treatments for osteoporosis and other conditions. This participation highlights Entera's progress and commitment to advancing its pipeline, including its lead product EB613, an oral osteoporosis treatment currently in Phase 2 trials.
Thomas Siebel, CEO of C3.ai, has sold 66,752 shares of the company to cover tax withholding obligations. This transaction is a routine financial move related to tax compliance rather than a strategic sale. Investors should note this is a standard pra...
The Amplify AI Powered Equity ETF (AIEQ) continues to underperform compared to the S&P 500 and other ETFs like IVV and QQQM, due to persistent structural weaknesses in its AI-driven investment strategy. Despite a very high turnover rate of 804%, AIEQ...
On September 19, attackers exploited SingularityNET's bridge infrastructure, releasing over 8.7 million Fetch.ai (FET) tokens and minting about 2.3 billion unauthorized tokens across four assets. The breach used compromised signing and minting privil...
Emerging market local currency debt recently outperformed other bond types but now faces challenges as the U.S. dollar strengthens and Federal Reserve rate hikes continue. The VanEck JP Morgan EM Local Currency Bond ETF, with its intermediate duratio...
Bitget decided to delist the DOG token while withdrawals were still suspended following a hack, leading to criticism from DOG founder Leonidas. He questioned the timing of the delisting notice, arguing it was unreasonable to announce it so soon after...
